Novel Drug Delivery Systems(NDDS):

Long-acting and extended release technology

Liposome and targeted drug delivery technology

Transdermal drug delivery technology

New Molecular Entities (NME):

New Chemical Entities (NCE): Based on innovative targets, they include novel small-molecule compounds and biologics like antibodies and nucleic acids.

Novel Therapeutic Entities (NTE): Including therapeutic entities with molecular modifications.

Peptide-Conjugated Drugs (PDC): The company has achieved key capabilities for discovering targets, designing drugs, and screening/evaluating candidates.

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

BA-huMab^® platform: The platform covers 30 κ light chain variable region genes of human antibodies and 110 heavy chain variable region genes (IgM&IgG1) of human antibodies. The antibodies can induce rapid immune responses and produce higher antibody titers after immunization. This method has been validated with a large number of antibodies.
Phage display technology platform: The platform uses novel vaccines and immunoadjuvants. It adopts a mature technique to build phage libraries as well as multiple high-throughput, phage-based panning strategies. The company has the ability to develop bispecific antibodies with common light chains.

Bispecific T-cell Engager Technology Platform:

The higher affinity with the targeted tumor antigens has been demonstrated through bivalent binding to achieve a higher efficacy of the drugs developed. And the lower affinity with T cells has been demonstrated through univalent binding to reduce toxicity. This strategy also reduces the affinity of CD3 antibody binding and therefore greatly reduces the risk of CRS. The company has developed trispecific CD3 antibodies targeting two tumor antigens, which can kill highly heterogeneous tumors more efficiently.

ADC Technology Platform:

The platform has a Top 1 inhibitor cytotoxic payload with excellent properties and antibodies with high internalizing potential. It uses a bispecific antibody ADC with a common light chain to deal with highly heterogeneous tumors and also adopts the fixed-point coupling technique. The company has the ability to develop manufacturing processes and conduct quality analysis for ADC products.

Nucleic Acid Therapy and Gene Therapy:

The company develops novel therapies such as nucleic acid therapy, which includes both mRNA and Oligo. They all harbor significant potential to address a wide spectrum of diseases.

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabler in nucleic acid or gene therapy.  The company’s proprietary LNP platform enables the tissue-specific or organ-specific delivery of gene and nucleic acid therapies.

CAR-T Cell Immunotherapy:

The company develops the next-generation cell therapy technologies engineered to target neo-tumor antigens and deliver other therapeutic functions. The novel non-viral vector technology is used to enhance the manufacturing efficiency. This strategy has the potential to improve cancer treatment by providing a personalized treatment option.